Michel Rives
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michel Rives has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Genebes
Department of Radiation Oncology, Institute Claudius Regaud, Toulouse, France
1 shared publication - Isabelle Fauquet
Department of Radiology, Clinique Pasteur, Toulouse, France
1 shared publication - Jean-Pierre Delord
Medical Oncology Department, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, CEDEX 09, 31059 Toulouse, France
1 shared publication - Sabrina Boyrie
Department of Radiotherapy, Institut Claudius Regaud, Toulouse, France
1 shared publication
Latest Publications
- Open Access
- 18 December 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 679
Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors.
- 18 December 2013
- Published by Springer Nature in SpringerPlus
- Vol. 2 (1) , 679
Open AccessCystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. We report the case of a patient with an aggressive cystadenocarcinoma of the parotid with synchronous metastases. Cisplatine/5FU chemotherapy associated with palliative radiation therapy was used first without any efficency nor clinical improvement. A molecular analysis revealed a BRAF mutation. A compassionate treatment with a BRAF inhibitor showed very good results from the first month. The patient reported real improvement in clinical condition and pain. From an imaging point of view, computed tomographies reported a complete response on mediastinal lymph nodes and regeneration on bone metastases. This first report suggests BRAF could be a potent oncogenic driver in salivary gland carcinoma. It deserves a multicenter academic prospective trial to provide proof of efficiency with BRAF inhibitors in theses tumors.